Table 1.
Literature | Study period | Study design | No. of patients | Biologic used | Rate of surgery | Follow-up |
---|---|---|---|---|---|---|
Schnitzler et al. (2009) [34] | 1994–2007 | Retrospective single-center | 614 | Infliximab | 23.5% | 55 months (median) |
Peyrin-Biroulet et al. (2016) [31] | 2000–2013 | Retrospective multi-center | 350 | Infliximab or adalimumab | 24.9% (calculated 5-year rate) | 33 months (median) |
Eshuis et al. (2013) [35] | 1993–2010 | Retrospective multi-center | 276* | Infliximab | 18% no prior surgery for CD; 24% prior surgery for CD | 54 months (median) |
Alzafir et al. (2011) [36] | 2002–2008 | Retrospective single-center | 71 | Infliximab | 7% | 62 months (median) |
Caviglia et al. (2007) [37] | 1999–2005 | Retrospective single-center | 40 | Infliximab | 20% | 27 months (median) |
Ljung et al. (2004) [38] | 1999–2001 | Population-based cohort | 191 | Infliximab | 17.2% | 24 months |
Feagan et al. (2008) [39] | 2000–2002 | Randomized–controlled trial | 65 | Vedoliuzimab | 9.2% | 24 months |
Subgroup of patients who underwent maintenance therapy.